T cells in tuberculosis: What type of T cell mediates immunity and how do we induce it by vaccination?
Lead Research Organisation:
University of Leicester
Department Name: Infection Immunity and Inflammation
Abstract
Vaccination is a powerful tool against disease but we have stalled in development of vaccines against some diseases. The reason for this failure is that we do not understand how the immune response, which is the target of the vaccine, actually controls these diseases. Tuberculosis (TB) is one such disease despite the current vaccine, BCG, being the most widely used vaccine in the world. Our ability to limit TB is constrained by the simple enormity of the problem with the current case rate being 1,000 times the rate required for elimination of disease. In order to reduce this rate we need to develop rapid diagnostics, short course drugs and an effective vaccine. TB represents a major challenge in vaccine development because we are trying to improve upon an immune response which is largely protective in the majority of individuals. There is also increasing evidence that immunity can be expressed within one lesion of a host and yet fail in another lesion within the same host. We do not know what is going wrong in the failing lesions or in those individuals where latent infection is progressing to active disease. In the work described here we will determine the factors that are critical to the generation of an immune response that is able to maintain protection throughout infection thereby limiting the incidence of disease. This work will help in the design of vaccines. Our working model is that some T cells are protective because they can penetrate and persist within the lesion whereas other vaccine-induced T cells fail because they are excluded from the lesion. Our purpose is to determine what promotes the generation of good T cell populations and what compromises the prolonged function of these T cells within mycobacterial lesions. We will manipulate the T cell and the environment and use confocal imaging, flow cytometry and bacterial burden to determine the functionality of specific subsets of T cells in the lung. By defining these factors we will develop a working model for the generation of T cells capable of functioning in the face of bacterially generated inflammation. This working model can then be integrated with experimental medicine studies and provide a basis for rational vaccine design.
Technical Summary
TB represents a major challenge in vaccine development because we do not know constitutes a protective T cell and this is a complex issue in TB as unrestrained T cell responses are pathogenic and T cells must function for prolonged periods in inflammatory lesions to maintain long-term control. We propose that in TB, inflammation limits T cell function in ways that we do not fully understand and that we do not know how to prime T cells that function optimally in inflamed TB lesions, nor do we know what factors limit efficacy of T cells in these lesions. Importantly, we and others have recently determined that antigen-specific CD4 T cells within Mtb lesions exist in novel phenotypic subsets; some express the surface markers PD1 and CD69 and others express the marker KLRG1. The PD-1posCD69pos cells produce IL-2, express the IL-2 and IL-7 receptors, require ICOS and the transcription factor Bcl6 and locate within the parenchyma whereas the KLRG1pos cells express very high levels of the transcription factor T-bet, require IL-27R expression, produce the cytokine IFN and locate within the vasculature. Importantly, when transferred to an Mtb-infected lung, the PD-1posCD69pos population persist while the KLRG1pos population do not and the PD-1posCD69pos CD4 T cells mediate improved bacterial control whereas the KLRG1pos CD4 T cells, while expressing high levels of IFN, do not. Our working model is that protective CD4 T cells penetrate and persist within the mycobacterial lesions but that many vaccine-induced CD4 T cells fail to do this. We hypothesize that TCR-mediated events during priming define the function of T cells and that manipulation of the mycobacterial lesion will permit optimal function of T cells. We will develop a working model of how to generate T cells that function in the context of mycobacterial lesions, which will underpin rational design of vaccine strategies, development of potential correlates of protection and development of host directed therapies.
Planned Impact
We all know the power of vaccination and how effective it is in eliminating infectious disease. While we have made excellent progress in developing vaccines for many infectious diseases we have failed to make ones that work against some of the world's most serious public health threats. One such failure is in the development of a vaccine which will eliminate tuberculosis (TB). TB is a major killer and a serious social and economic burden for the vast majority of the world's population. The current case rate is dropping (very slowly) but there is no sign that this disease will be eliminated in our lifetime. What is needed is new diagnostics, new short course drug therapy and a vaccine capable of eliminating the risk of disease in all those vaccinated. The work proposed in this application will provide basic scientific data regarding the best way to induce T cells capable of controlling infection indefinitely (i.e. stopping disease) as well as how to release the capacity of T cells to eliminate the infection (i.e. function effectively). The work is performed in an animal model because we cannot control the experimental parameters sufficiently in human studies in order to gather the type of information needed. However the data sets generated in this work will be actively integrated with human studies in patients and in healthy contacts which will allow us to build a working model of how T cells should be induced and how they can behave during infection.
The principal audience for the work performed here will be other scientists investigating the role of T cells in immune disease, those studying TB in model systems and in humans and those interested in developing/enhancing vaccine delivery systems. While the first two groups are likely publically-funded researchers the latter group includes industry-funded academics.
In the mid to long term the work performed here will be integrated with work from others within the field. This integration will result in a working model of the causes of TB pathogenesis and the development of rational interventions which limit disease occurrence and transmission. The rational interventions to be impacted will be the capacity to design vaccines based on what we know we want (rather than simply guessing) as well as the development/support for host directed therapy pathways which can unleash the power of the T cell response without promoting pathologic consequences.
The beneficiaries of this work are the post-doctoral and technical staff who will obtain training in techniques, intellectual rigour and scientific communication. The Investigator will benefit from being able to pursue her hypotheses and to contribute to the eventual development of an effective vaccine.
Direct effects on TB management in the UK is not a target of this work, however those working with patients in Leicester will be able to benefit from any new developments regarding T cell function identified in the proposed work.
The milestones to be achieved will be:
1. Identification of the role of TCR signal in driving protective T cells - will impact how we vaccinate
2. Identification of the role of IL-2 in development of protective T cells - will impact what we look for when we vaccinate
3. Identification of the role of T cell differentiation in driving protective T cells - will impact how we vaccinate and what we look for following vaccination.
4. Identification of the role of nitric oxide production in regulating T cells- will impact whether we can intervene to allow host responses to work better
5. Identification of the role of T cell intrinsic factors in defining efficacy of T cells- will impact how we vaccinate and whether we can intervene during disease.
6. Determine the functional capacity of T cells with regarding the location and persistence in vivo- will impact whether we can intervene and what to look for as a correlate of protection post vaccination.
The principal audience for the work performed here will be other scientists investigating the role of T cells in immune disease, those studying TB in model systems and in humans and those interested in developing/enhancing vaccine delivery systems. While the first two groups are likely publically-funded researchers the latter group includes industry-funded academics.
In the mid to long term the work performed here will be integrated with work from others within the field. This integration will result in a working model of the causes of TB pathogenesis and the development of rational interventions which limit disease occurrence and transmission. The rational interventions to be impacted will be the capacity to design vaccines based on what we know we want (rather than simply guessing) as well as the development/support for host directed therapy pathways which can unleash the power of the T cell response without promoting pathologic consequences.
The beneficiaries of this work are the post-doctoral and technical staff who will obtain training in techniques, intellectual rigour and scientific communication. The Investigator will benefit from being able to pursue her hypotheses and to contribute to the eventual development of an effective vaccine.
Direct effects on TB management in the UK is not a target of this work, however those working with patients in Leicester will be able to benefit from any new developments regarding T cell function identified in the proposed work.
The milestones to be achieved will be:
1. Identification of the role of TCR signal in driving protective T cells - will impact how we vaccinate
2. Identification of the role of IL-2 in development of protective T cells - will impact what we look for when we vaccinate
3. Identification of the role of T cell differentiation in driving protective T cells - will impact how we vaccinate and what we look for following vaccination.
4. Identification of the role of nitric oxide production in regulating T cells- will impact whether we can intervene to allow host responses to work better
5. Identification of the role of T cell intrinsic factors in defining efficacy of T cells- will impact how we vaccinate and whether we can intervene during disease.
6. Determine the functional capacity of T cells with regarding the location and persistence in vivo- will impact whether we can intervene and what to look for as a correlate of protection post vaccination.
Publications
Alam F
(2020)
CD25-Targeted IL-2 Signals Promote Improved Outcomes of Influenza Infection and Boost Memory CD4 T Cell Formation.
in Journal of immunology (Baltimore, Md. : 1950)
Apt AS
(2023)
Editorial: Mycobacteria-host interactions: genetics, immunity, pathology volume II.
in Frontiers in cellular and infection microbiology
Cooper AM
(2017)
Defining the Kinetics, Phenotype, and Function of T Cells Induced by Mycobacterium tuberculosis: Pillar of Immunity to Tuberculosis.
in Journal of immunology (Baltimore, Md. : 1950)
Cossarizza A
(2019)
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
in European Journal of Immunology
García-Bengoa M
(2023)
Immunogenicity of PE18, PE31, and PPE26 proteins from Mycobacterium tuberculosis in humans and mice
in Frontiers in Immunology
Hutchinson GM
(2022)
Effect of high intensity interval training and moderate intensity continuous training on lymphoid, myeloid and inflammatory cells in kidney transplant recipients.
in Exercise immunology review
Martin C
(2023)
Ethnic differences in cellular and humoral immune responses to SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis
in eClinicalMedicine
McKinstry KK
(2019)
Memory CD4 T cell-derived IL-2 synergizes with viral infection to exacerbate lung inflammation.
in PLoS pathogens
Pearl JE
(2018)
Immunological roulette: Luck or something more? Considering the connections between host and environment in TB.
in Cellular & molecular immunology
Description | Contributed to the WHO TB white paper on TB vaccine design |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Membership of a guideline committee |
Description | Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition) |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | UK-REACH: United Kingdom Research Study into Ethnicity And COVID-19 outcomes in Healthcare workers |
Amount | £2,146,067 (GBP) |
Funding ID | MR/V027549/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 08/2020 |
End | 10/2022 |
Description | Wellcome Trust Multi-User Equipment Scheme |
Amount | £290,555 (GBP) |
Funding ID | 208393/Z/17/Z |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2018 |
End | 12/2022 |
Title | Flow cytometry outreach |
Description | We have improved the availability and sophistication of the flow cytometric activity with the College of Life Sciences at Leicester. We have organized training for 34 researchers and collaborated directly with 4 research groups to augment the depth of discovery they can achieve with the flow cytometric equipment in my laboratory. |
Type Of Material | Improvements to research infrastructure |
Year Produced | 2017 |
Provided To Others? | Yes |
Impact | 34 Researchers in the College of Life Sciences have achieved a basic understanding of low cytometry - documented. |
Title | Implemented a bespoke aerosol exposure machine available to colleagues |
Description | We have designed and built a bespoke aerosol delivery device which can use a variety of aerosol generators and can have sensors added to the aerosol chamber to measure particle size humidity etc. This machine is one of only a few aerosol generating facilities in the UK and has a work flow allowing assessment of microbiological, immunological and physiological outcomes to be measured after aerosol exposure to category 3 pathogens. |
Type Of Material | Improvements to research infrastructure |
Year Produced | 2019 |
Provided To Others? | Yes |
Impact | Yet to be determined |
Title | Maintained research activity for College throughout pandemic |
Description | Its a bit cheeky to put this here but I was instrumental with my team for ensuring that critical research activity was continuous throughout the pandemice here at Leicester. The most important element was having a preparedness plan in place for the animal facility. This plan was initiated by mysefl and my team in Feb 2020 and resulted in all ongoing experiments being undertekn within the facikity to be completed and for colonies to be maintained. |
Type Of Material | Improvements to research infrastructure |
Year Produced | 2021 |
Provided To Others? | No |
Impact | Continued activity within the animal facility - no undue harms to animals and completion of funded research. |
Title | Vaccines Sulman et al 2021 |
Description | This is the core data for the paper Balance between Protection and Pathogenic Response to Aerosol Challenge with Mycobacterium tuberculosis (Mtb) in Mice Vaccinated with TriFu64, a Fusion Consisting of Three Mtb Antigens |
Type Of Material | Database/Collection of data |
Year Produced | 2021 |
Provided To Others? | Yes |
URL | https://leicester.figshare.com/articles/dataset/Vaccines_Sulman_et_al_2021/14607879 |
Description | TBVI |
Organisation | Tuberculosis Vaccine Initiative (TBVI) |
Country | Netherlands |
Sector | Charity/Non Profit |
PI Contribution | I have been invited to join the steering committee of The TuBerculosis Vaccine Initiative (TBVI), which is a Research and Innovation partnership that facilitates the discovery and development of new, safe and effective TB vaccines that are accessible and affordable for all people. As a non-profit foundation, TBVI creates an enabling environment for TB vaccine research and innovation (R&I) and product development. TBVI supports its R&D partners with the development and move the most promising TB vaccine and biomarker candidates through the pipeline. To continue to innovate and diversify the pipeline and TB vaccine platforms, TBVI supports collaborative research and innovation by its R&D partners. TBVI adds value through providing services of technical advice for product development; project identification, development and management; and resource mobilisation. TBVI works through the Global TB Vaccine Partnership (GTBVP) with global stakeholders to strengthen Global and European cooperation and coordination and identifies gaps to move the field forward. |
Collaborator Contribution | The steering committee works together to overcome road blocks to TB vaccine design. |
Impact | WE are developing and propose to submit grant applications. |
Start Year | 2021 |
Description | The VALIDATE Network - Vaccine development for complex intracellular neglected pathogens |
Organisation | London School of Hygiene and Tropical Medicine (LSHTM) |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | VALIDATE is an international network of researchers developing vaccines against globally significant diseases caused by complex intracellular pathogens. Our initial focus is on tuberculosis (TB), leishmaniasis, melioidosis, and leprosy, which cause substantial mortality and morbidity across the globe, particularly in low and middle-income countries (LMICs). By working together, we will advance research more quickly and effectively |
Collaborator Contribution | VALIDATE's vision is to accelerate vaccine R&D for TB, leishmaniasis, melioidosis and leprosy by creating an engaged and interactive community of researchers who form new cross-pathogen, cross-continent, cross-species and cross-discipline collaborations, generating new ideas, taking advantage of synergies and quickly disseminating lessons learned across the Network. We provide pump-priming grants for ground-breaking projects by members. We also aim to facilitate continuing professional development (CPD) and career progression among our members, particularly Early Career and LMIC Researchers, by providing training grants, workshops, a mentoring scheme and seminars, as well as this central hub website highlighting job and training opportunities worldwide. |
Impact | https://www.validate-network.org/funded-pump-priming-projectshttps://www.validate-network.org/training-grants-0 |
Start Year | 2017 |
Description | The VALIDATE Network - Vaccine development for complex intracellular neglected pathogens |
Organisation | University of Oxford |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | VALIDATE is an international network of researchers developing vaccines against globally significant diseases caused by complex intracellular pathogens. Our initial focus is on tuberculosis (TB), leishmaniasis, melioidosis, and leprosy, which cause substantial mortality and morbidity across the globe, particularly in low and middle-income countries (LMICs). By working together, we will advance research more quickly and effectively |
Collaborator Contribution | VALIDATE's vision is to accelerate vaccine R&D for TB, leishmaniasis, melioidosis and leprosy by creating an engaged and interactive community of researchers who form new cross-pathogen, cross-continent, cross-species and cross-discipline collaborations, generating new ideas, taking advantage of synergies and quickly disseminating lessons learned across the Network. We provide pump-priming grants for ground-breaking projects by members. We also aim to facilitate continuing professional development (CPD) and career progression among our members, particularly Early Career and LMIC Researchers, by providing training grants, workshops, a mentoring scheme and seminars, as well as this central hub website highlighting job and training opportunities worldwide. |
Impact | https://www.validate-network.org/funded-pump-priming-projectshttps://www.validate-network.org/training-grants-0 |
Start Year | 2017 |
Description | The VALIDATE Network - Vaccine development for complex intracellular neglected pathogens |
Organisation | University of York |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | VALIDATE is an international network of researchers developing vaccines against globally significant diseases caused by complex intracellular pathogens. Our initial focus is on tuberculosis (TB), leishmaniasis, melioidosis, and leprosy, which cause substantial mortality and morbidity across the globe, particularly in low and middle-income countries (LMICs). By working together, we will advance research more quickly and effectively |
Collaborator Contribution | VALIDATE's vision is to accelerate vaccine R&D for TB, leishmaniasis, melioidosis and leprosy by creating an engaged and interactive community of researchers who form new cross-pathogen, cross-continent, cross-species and cross-discipline collaborations, generating new ideas, taking advantage of synergies and quickly disseminating lessons learned across the Network. We provide pump-priming grants for ground-breaking projects by members. We also aim to facilitate continuing professional development (CPD) and career progression among our members, particularly Early Career and LMIC Researchers, by providing training grants, workshops, a mentoring scheme and seminars, as well as this central hub website highlighting job and training opportunities worldwide. |
Impact | https://www.validate-network.org/funded-pump-priming-projectshttps://www.validate-network.org/training-grants-0 |
Start Year | 2017 |
Description | BSI winter school - lecture |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | I was a member of faculty for the British Society of Immunology Winter school where we interacted with Masters students from UK. Engaging them in the wonders of immunology and looking at their careers as scientists. |
Year(s) Of Engagement Activity | 2018 |
Description | Hosting sixth form students in laboratory |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | I hosted a sixth form student in the laboratory. They attended for a week and were exposed to scientific method, technical activity and scientific discussion. the goal was to encourage a career in scientific field and to promote scholarly discussion among the public. |
Year(s) Of Engagement Activity | 2018 |
Description | Outreach Career activity Oakham school |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Schools |
Results and Impact | I attended a career fair for years 11-13 and communicated the career path of a scientific researcher. |
Year(s) Of Engagement Activity | 2019 |
Description | Outreach STEM School Leicester |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | I attended a workshop with lower sixth students who were learning how to interact with professional people. I represented the research active professor at a university. I encouraged students to pursue career in the sciences. |
Year(s) Of Engagement Activity | 2019 |
Description | Outreach Sixth form students in the lab for a week in summer |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | Hosted two sixth form puils in the laboratory for one week work experience. One now entering Cambridge for natural sciences the other looking for admission for engineering in 2022 |
Year(s) Of Engagement Activity | 2021 |
Description | Respiratory Lunchtime talk - Glenfield |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | Gave a talk on my own work to clinical respiratory physicians. |
Year(s) Of Engagement Activity | 2018 |
Description | TB Day |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Postgraduate students |
Results and Impact | We held a TB Day workshop entitled Reality TB: The truth about TB in Leicester and how we are making a difference. The audience consisted of medical, nursing, research, patients, advocates, and general public. The theme of the workshop was 'the experience of TB across different communities'. There was lively discussion for all groups and the event was reported on the local radio. |
Year(s) Of Engagement Activity | 2017 |
Description | TB Day activity outreach |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Industry/Business |
Results and Impact | Discussion of outbreak activity in Leicester with clinical, research and diagnostic/public health experts |
Year(s) Of Engagement Activity | 2019 |
Description | Visit to sixth form students local school |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | I visited the local school to engage students in discussion about their career choices . My goal was to excite them about their ability to be a part of scientific research endeavor |
Year(s) Of Engagement Activity | 2018 |
Description | Wellcome Trust Midlands town hall event |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | We hosted a regional Townhall to provide a space for the research community to come together to digest the Wellcome Trusts survey's findings, reflecting on what a better culture would look like, showcase the great work that institutions are already doing and share ideas for how Wellcome and other actors in the system could change. We hosted leaders at Universities in the region |
Year(s) Of Engagement Activity | 2020 |